10-Q quarterly report · filed Nov 3, 2026

Beam Therapeutics Inc. (BEAM) Q3 2026 10-Q Quarterly Report

Short answer

Beam Therapeutics Inc. (BEAM) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $307,000 (down 96.8% year over year) with net income of −$134M.

Q3 2026 key financials · XBRL

Revenue
$307,000
−96.8% YoY · −37.3% QoQ
Net income
−$134M
−19.2% YoY · −9.6% QoQ
Operating margin
-46033.2%
EPS (diluted)
−$1.29
−18.3% YoY · −9.3% QoQ

Source: XBRL data from the Beam Therapeutics Inc. (BEAM) Q3 2026 10-Q on SEC EDGAR. USD.

Beam Therapeutics Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $0.3M, down $9.4M from $9.7M YoY
  • Net loss $134.4M vs $112.6M YoY, operating loss $141.3M vs $126.8M
  • R&D expense $110.1M vs $109.8M, G&A $31.5M vs $26.7M
  • Cash, equivalents and marketable securities $1.0B; operating cash outflow $305.4M
  • BEAM-302 expansion ongoing, pivotal-cohort dosing expected complete in first half of 2027; additional capital likely needed

Risk Factors

  • No material risk-factor changes identified relative to the 2025 Form 10-K
  • Financing risk: $100.4 million debt outstanding at 10.6% effective interest, maturing February 24, 2033
  • Liquidity risk: $1.0 billion cash, equivalents, and marketable securities expected to fund operations for at least 12 months
  • Regulatory risk: risto-cel development and commercialization subject to FDA acceptance and approval milestones
  • Collaboration risk: Biogen termination of FcRN program rights effective December 2026 ઘટાડે future collaboration potential

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Beam Therapeutics Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.